SCHEMBL3336874

SCHEMBL3336874

CN1CCC=C(CO)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8325048 0.80
SCHEMBL13900957 0.78 CHRM1 (0.47)
SCHEMBL10841100 0.77
SCHEMBL6635136 0.77 CHRM1 (0.42)
Hydrochloric Acid SCHEMBL1897876 0.77 CHRNB2 (0.42)
SCHEMBL9499202 0.76 CHRNB2 (0.50)
SCHEMBL9130174 0.75 CHRM2 (0.48)
SCHEMBL10740679 0.74 CHRNB2 (0.43)
SCHEMBL10741620 0.74 CHRNB2 (0.40)
SCHEMBL10741609 0.74 CHRNB2 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336562-A1 COMPOUND SERVING AS NLRP3 INHIBITOR HANGZHOU INNOGATE PHARMA CO., LTD. (CN) 2024-10-10 US disclosed
CN-117279903-A Compounds as NLRP3 inhibitors 杭州英创医药科技有限公司 2023-12-22 CN disclosed
EP-4293018-A1 COMPOUND SERVING AS NLRP3 INHIBITOR Hangzhou Innogate Pharma Co., Ltd. (CN) 2023-12-20 EP disclosed
WO-2022171185-A1 COMPOUND SERVING AS NLRP3 INHIBITOR 杭州英创医药科技有限公司 2022-08-18 WO disclosed
US-20140303372-A1 SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BHAMAS LTD. (BS) 2014-10-09 US disclosed
US-20140303372-A1 SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BHAMAS LTD. (BS) 2014-10-09 US disclosed
US-20140303372-A1 SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BHAMAS LTD. (BS) 2014-10-09 US disclosed
US-8722887-B2 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbvie Bahamas, Ltd. (BS) 2014-05-13 US disclosed
US-8722887-B2 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbvie Bahamas, Ltd. (BS) 2014-05-13 US disclosed
US-8722887-B2 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbvie Bahamas, Ltd. (BS) 2014-05-13 US disclosed
WO-2008034863-A2 SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2008-03-27 WO disclosed
WO-2008034863-A2 SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2008-03-27 WO disclosed
US-6774132-B1 Spirooxindole derivatives that act as analgesics ASTRAZENECA AB (SE) 2004-08-10 US disclosed
EP-1426375-A2 Analgesic spiroindole derivatives AstraZeneca AB (SE) 2004-06-09 EP disclosed
US-20040087800-A1 Spirooxindole derivatives are analgesics for the treatment of chronic pain. ASTRAZENECA AB 2004-05-06 US disclosed
EP-1202994-B1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2004-04-14 EP disclosed
EP-0284395-B1 NOVEL GLYCEROL DERIVATIVE AND ANTI-HYPERTENSIVE AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 1993-06-23 EP disclosed
US-5183811-A Glycerol derivative and anti-hypertensive agent NIPPON CHEMIPHAR CO., LTD. (JP) 1993-02-02 US disclosed
US-4962096-A WITH REDUCED PLATELET AGGREGATING ACTION NIPPON CHEMIPHAR CO., LTD. (JP) 1990-10-09 US disclosed
EP-0284395-A2 Novel glycerol derivative and anti-hypertensive agent NIPPON CHEMIPHAR CO., LTD. (JP) 1988-09-28 EP disclosed